Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.

Germ line inactivating mutations in BRCA1 confer susceptibility for breast and ovarian cancer. However, the relevance of the many missense changes in the gene for which the effect on protein function is unknown remains unclear. Determination of which variants are causally associated with cancer is important for assessment of individual risk. We used a functional assay that measures the transactivation activity of BRCA1 in combination with analysis of protein modeling based on the structure of BRCA1 BRCT domains. In addition, the information generated was interpreted in light of genetic data. We determined the predicted cancer association of 22 BRCA1 variants and verified that the common polymorphism S1613G has no effect on BRCA1 function, even when combined with other rare variants. We estimated the specificity and sensitivity of the assay, and by meta-analysis of 47 variants, we show that variants with <45% of wild-type activity can be classified as deleterious whereas variants with >50% can be classified as neutral. In conclusion, we did functional and structure-based analyses on a large series of BRCA1 missense variants and defined a tentative threshold activity for the classification missense variants. By interpreting the validated functional data in light of additional clinical and structural evidence, we conclude that it is possible to classify all missense variants in the BRCA1 COOH-terminal region. These results bring functional assays for BRCA1 closer to clinical applicability.

[1]  Andrej Sali,et al.  Functional Impact of Missense Variants in BRCA1 Predicted by Supervised Learning , 2006, PLoS Comput. Biol..

[2]  F. Couch,et al.  Functional assays for BRCA1 and BRCA2. , 2007, The international journal of biochemistry & cell biology.

[3]  J. Hopper,et al.  Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. , 2006, Cancer research.

[4]  T. Katagiri,et al.  Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. , 2006, Human molecular genetics.

[5]  F. Couch,et al.  Cancer risk assessment at the atomic level. , 2006, Cancer research.

[6]  A. Zharkikh,et al.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral , 2005, Journal of Medical Genetics.

[7]  B. Ward,et al.  Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. , 2005, Cancer research.

[8]  L. Esserman,et al.  Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. , 2005, JAMA.

[9]  A. Varma,et al.  Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex. , 2005, Biochemistry.

[10]  S. Neuhausen,et al.  Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families , 2005, Cancer Epidemiology Biomarkers & Prevention.

[11]  B. Haffty,et al.  Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women , 2005, Journal of Medical Genetics.

[12]  F. Barany,et al.  Classification of BRCA1 missense variants of unknown clinical significance , 2005, Journal of Medical Genetics.

[13]  B. Henderson,et al.  BRCA1 variants in a family study of African-American and Latina women , 2005, Human Genetics.

[14]  J. Glover,et al.  Interactions between BRCT repeats and phosphoproteins: tangled up in two. , 2004, Trends in biochemical sciences.

[15]  F. Couch,et al.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.

[16]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[17]  S. Macura,et al.  Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. , 2004, Structure.

[18]  A. Zharkikh,et al.  Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation , 2004, Journal of Medical Genetics.

[19]  C. Szabo,et al.  Understanding Germ-Line Mutations in BRCA1 , 2004, Cancer biology & therapy.

[20]  Drew M. Lowery,et al.  Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer , 2004, Nature Structural &Molecular Biology.

[21]  Nebojsa Mirkovic,et al.  Structure-Based Assessment of Missense Mutations in Human BRCA1 , 2004, Cancer Research.

[22]  J. Glover,et al.  Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1 , 2004, Nature Structural &Molecular Biology.

[23]  Yigong Shi,et al.  Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. , 2004, Molecular cell.

[24]  Lawrence C. Brody,et al.  Functional Characterization of BRCA1 Sequence Variants using a Yeast Small Colony Phenotype Assay , 2004, Cancer biology & therapy.

[25]  Junjie Chen,et al.  Phosphopeptide Binding Specificities of BRCA1 COOH-terminal (BRCT) Domains* , 2003, Journal of Biological Chemistry.

[26]  Michael B Yaffe,et al.  BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting , 2003, Science.

[27]  Georges Mer,et al.  The BRCT Domain Is a Phospho-Protein Binding Domain , 2003, Science.

[28]  Douglas F Easton,et al.  A full-likelihood method for the evaluation of causality of sequence variants from family data. , 2003, American journal of human genetics.

[29]  J. Potter,et al.  Understanding missense mutations in the BRCA1 gene: An evolutionary approach , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Desmond J. Smith,et al.  The allelic structure of common disease. , 2002, Human molecular genetics.

[31]  S. Narod,et al.  Genetic counselling for familial breast and ovarian cancer in Ontario , 2002, Journal of medical genetics.

[32]  L. Serpell,et al.  Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor , 2002, The EMBO journal.

[33]  D. Livingston,et al.  Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. , 2002, Genes & development.

[34]  P. Møller,et al.  Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. , 2001, Human molecular genetics.

[35]  K Karplus,et al.  What is the value added by human intervention in protein structure prediction? , 2001, Proteins.

[36]  A. Monteiro,et al.  Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. , 2000, Cancer research.

[37]  R. Modali,et al.  BRCA1 mutations in African Americans , 1999, Human Genetics.

[38]  H. Hanafusa,et al.  Common BRCA1 variants and transcriptional activation. , 1997, American journal of human genetics.

[39]  F. Collins,et al.  Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Clayton,et al.  Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. , 1997, Human molecular genetics.

[41]  H. Hanafusa,et al.  Evidence for a transcriptional activation function of BRCA1 C-terminal region. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  I. Verma,et al.  Transcriptional activation by BRCA1 , 1996, Nature.

[43]  R. Brent,et al.  Correlation of two-hybrid affinity data with in vitro measurements , 1995, Molecular and cellular biology.

[44]  Patrick Dowd,et al.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families , 1994, Nature Genetics.

[45]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[46]  L Serrano,et al.  The folding of an enzyme. II. Substructure of barnase and the contribution of different interactions to protein stability. , 1992, Journal of molecular biology.

[47]  A. Fersht,et al.  The folding of an enzyme. I. Theory of protein engineering analysis of stability and pathway of protein folding. , 1992, Journal of molecular biology.

[48]  Thomas J. White,et al.  PCR protocols: a guide to methods and applications. , 1990 .

[49]  Georges Mer,et al.  The BRCT Domain Is a PhosphoProtein Binding Domain , 2022 .